top of page
< Back

Lenvatinib


Mechanism of action:

Lenvatinib is a small-molecule multi-target tyrosine kinase inhibitor. Lenvatinib inhibits the tyrosine kinase activity of receptors such as VEGFR1-3 and FGFR1-4. By blocking these receptors, it suppresses tumor angiogenesis, reduces tumor blood flow and oxygen supply, and inhibits downstream signaling pathways involved in proliferation and survival.

Reference(s):

1. Matsui J et al. (2008). E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 


2. Glen H et al. (2011). E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion. BMC Cancer. 


3. Scott LJ et al. (2015). Lenvatinib: first global approval. Drugs.

bottom of page